About Low-density lipoprotein receptor class A domain-containing protein 4
Low-density lipoprotein receptor class A domain-containing protein 4 (LDLRAD4) is a protein
from Homo sapiens identified by UniProt accession
O15165, 306 residues long.
MolForge cross-references it against 0 known binders and
75 disease associations.
Target properties
| Protein name | Low-density lipoprotein receptor class A domain-containing protein 4 |
|---|
| UniProt accession | O15165 |
|---|
| Gene | LDLRAD4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 306 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (75)
Diseases linked to this target (Open Targets).
- body mass index · score 0.48
- neurodegenerative disease · score 0.45
- body weight · score 0.44
- body fat percentage · score 0.44
- lean body mass · score 0.42
- fat body mass · score 0.40
- platelet crit · score 0.36
- adverse effect · score 0.34
- gut microbiome measurement · score 0.33
- bone density · score 0.32
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O15165-F1 | alphafold | PREDICTED | 58.69 | — |
Amino-acid sequence (306 residues)
MPEAGFQATN AFTECKFTCT SGKCLYLGSL VCNQQNDCGD NSDEENCLLV TEHPPPGIFN SELEFAQIII IVVVVTVMVV VIVCLLNHYK VSTRSFINRP NQSRRREDGL PQEGCLWPSD SAAPRLGASE IMHAPRSRDR FTAPSFIQRD RFSRFQPTYP YVQHEIDLPP TISLSDGEEP PPYQGPCTLQ LRDPEQQMEL NRESVRAPPN RTIFDSDLID IAMYSGGPCP PSSNSGISAS TCSSNGRMEG PPPTYSEVMG HHPGASFLHH QRSNAHRGSR LQFQQNNAES TIVPIKGKDR KPGNLV
Explore Low-density lipoprotein receptor class A domain-containing protein 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets